Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Lysosomal storage diseases (LSDs) often manifest with severe systemic and central nervous system (CNS) symptoms. The existing treatment options are limited and have no or only modest efficacy against neurological manifestations of disease. We demonstrate that recombinant human heat shock protein 70 (HSP70) improves the binding of several sphingolipid-degrading enzymes to their essential cofactor bis(monoacyl)glycerophosphate in vitro. HSP70 treatment reversed lysosomal pathology in primary fibroblasts from 14 patients with eight different LSDs. HSP70 penetrated effectively into murine tissues including the CNS and inhibited glycosphingolipid accumulation in murine models of Fabry disease (Gla(-/-)), Sandhoff disease (Hexb(-/-)), and Niemann-Pick disease type C (Npc1(-/-)) and attenuated a wide spectrum of disease-associated neurological symptoms in Hexb(-/-) and Npc1(-/-) mice. Oral administration of arimoclomol, a small-molecule coinducer of HSPs that is currently in clinical trials for Niemann-Pick disease type C (NPC), recapitulated the effects of recombinant human HSP70, suggesting that heat shock protein-based therapies merit clinical evaluation for treating LSDs.

Original publication

DOI

10.1126/scitranslmed.aad9823

Type

Journal article

Journal

Sci Transl Med

Publication Date

07/09/2016

Volume

8

Keywords

Administration, Intravenous, Animals, Blood-Brain Barrier, Bone Morphogenetic Proteins, Disease Models, Animal, Disease Progression, Fabry Disease, Fibroblasts, Glycosphingolipids, Heat-Shock Proteins, Humans, Hydroxylamines, Injections, Intraperitoneal, Intracellular Signaling Peptides and Proteins, Lysosomes, Niemann-Pick Disease, Type C, Proteins, Recombinant Proteins, Sphingolipidoses, Tissue Distribution